https://doi.org/10.31288/oftalmolzh201344044

The effect of intravitreal ranibizumab injection on eye hemodynamic in patients with diabetic cystoid macular edema study

Ponomarchuk V. S., Khramenko N. I., Rozanova Z. A., Maher Alzein

SI «Filatov Institute of Eye Diseases and Tissue Therapy of National Academy of Medical Science», Odessa, Ukraine

Key words: diabetic macular edema, rheoophthalmography

31 patient (41 eyes) with cystoid macular edema were divided into 2groups by age (group 1—40—59years, 16 patients, 19 eyes and group 2 — more than 60 years, 15 patients, 22 eyes) and rheographic factors RQ and a/T before intravitreal ranibizumab injection(IRI) and 1, 3, 6 months and 1 year after were investigated and compared with age norm. Repeating courses of metabolic and vascular protecting therapy were administrated immediately after IRI and 3, 6 months subsequently. During a year 1 IRI administrated on 3 eyes (7,3 %), 2 IRI on 10 eyes (24,4 %), and 3 IRI on 28 eyes (68,3 %).

Rheographic factors RQ and a/T tended to decrease before treatment, 1 months after in group 1, and 3 months after in group 2 factor RQ was approaching the normal and remained at that level through one year follow-up, no statistically sig-nificant differences from the age norm was found. IRI has insignificant effect on choroidal blood supply on patients with cystoid macular edema.

References

1.Alekseeva LL, Noeva AP. Hemodynamic changes in diabetic retinopathy in patients with diabetes mellitus. Vestnik SFVU. 2010; 7(4): 27—31. Russian.

2.Yeliseeva TO, Bishele NA. Елисеева T. О. Using vasoac-tive drugs for ischemic diseases treatment of the optic nerve and retina. RMZh. 2000; S(1): 10—3. Russian.

3.Korol AR, Mikheitseva IN, Kustrin TB et al. Effect of in-travitreal administration of ranibizumab, pegaptanib sodium and bevacizumab on hemodynamics of rabbits eyes. Tavricheskii medico-biologicheskii vestnik. 2012; 15(3): 74—7. Russian.

4.Korol AR, Khramenko NI, Zadorozhnyi OS et al. Drug cor-rection by angiogenesis inhibitors in hemodynamic disorders in the choroid in patients with exudative age-related macular degeneration. Oftalmol Zh. 2013; 2: 51—5. Russian.

5.Kuzovnikov VV, Nevmerzhitskaya VA, Lazarenko VI. Analysis of the effectiveness of medical and laser treatment for diabetic retinopathy. Kazanskii meditsinskii zhurnal. 2012; 93(4): 594— 7. Russian.
Crossref

6.Lazarenko VI. Functional rheography of the eye. Kras-noyarsk: Rastr; 2000. 160 p.

7.Neroyev VV, Kisileva TN, Ryabina MV. Effect of ranibizumab on hemodynamics in the vessels of the eye in patients with the wet form of AMD. Proceedings of V Russian seminar «Macula - 2012». Rostov-on-Don. 2012: 4S1—

8. Pasyechnikova NV, Naumenko VA, Zborovskaya AV. Clinic classification and laser treatment tactic in patients with diabetic macular edema. Odeskyi medychnyi zhurnal. 2009;116(6): 77—9. Russian.

9. Sdobnikova SV, Bolbas ZV, Galoyan NS et al. Effect of intravitreal injections of Lucentis on hemodynamics of the eye (pilot report). Proceedings of V Russian seminar «Macula — 2012». Rostov-on-Don. 2012: 235- 7.

10.Bunce C, Wormald R. Causes of blind certifications in Eng-land and Wales. Eye. 008; 22(7): 905- 11.
Crossref

11.Elman MJ, Aiello PA, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triam-cinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010; 117: 1064 - 77.
Crossref

12.Dimitrova G, Kato S, Tamaki Y et al. Choroidal circulation in diabetic patients. Eye. 200;10: 602-7.
Crossref

13.Klein R, Klein BE, Moss SE et al. TheWisconsin Epide-miologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabeticretinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998; 105(10):1801-15.
Crossref

14.Mitchell P, Bandello F, Schmidt-Erfurth U et al. The RE-STORE Study Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy for Diabetic Macular Edema. Ophthalmology. 2011;118: 615- 25.
Crossref

15.Nguyen QD, Brown DM, Marcus DM et al. Ranibizum-ab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. RISE and RIDE Research Group. Ophthalmology. 2012; 119(4): 789801.

16.Wang H, Sun X, Liu K et al. Intravitreal ranibizumab (lu-centis) for the treatment of diabetic macular edema: a sys-tematic review and meta-analysis of randomized clinical control trials. Curr Eye Res. 2012; 37(8): 661- 70.
Crossref